Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials
Author:
- B.J. GershBGB.J. Gersh
- 1 January 2008
- journal article
- Published by Elsevier in Yearbook of Cardiology
- Vol. 2008, 269-271
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Angiographic Surrogate End Points in Drug-Eluting Stent TrialsJACC, 2008
- Defining and Utilizing Surrogates in the Evaluation of Coronary StentsJACC, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996